University of Patras   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Patras Greece (1964)

Organization Overview

First Clinical Trial
2004
NCT01269125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Agios Andreas General State Hospital of Patras | Associate Professor of Ophthalmology, Medical School, University of Patras, Greece | Department of Anesthesia and Intensive Care Medicine, University Hospital of Patras | Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras | Division of Oncology,Dept of Internal Medicine,University Hospital of Patras | Medical School, University of Patras, Greece | Patras University | Patras University Hospital, Patras | Rio University Hospital of Patras | University General Hospital of Patras | University Hospital of Patras | University Hospital of Patras, Greece | University of Patras | University of Patras, Departement of Anesthesiology and Critical Care Medicine | University of Patras, Dept. of Anaesthesiology and Critical Care Medicine | University of Patras Medical School

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Body Weight (Phase 4)

Breast Neoplasms (Phase 2)

Capsule Opacification (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Fever (Phase 4)

Hypertension (Phase 4)

Infarction (Phase 4)

Kidney Failure, Chronic (Phase 3)

Multiple Myeloma (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Neoplasms, Plasma Cell (Phase 2)

Obesity (Phase 3)

Obesity, Morbid (Phase 3)

Ocular Hypertension (Phase 4)

Pain, Postoperative (Phase 3)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Sepsis (Phase 3)

ST Elevation Myocardial Infarction (Phase 4)

Stillbirth (Phase 3)

Syndrome (Phase 4)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial APIs: 39